NeuroVia starts Phase l/ll trial of NV1205 for CCALD
NeuroVia has commenced a Phase l/ll clinical trial of NV1205 for the treatment of patients with childhood cerebral adrenoleukodystrophy (CCALD).
NeuroVia has commenced a Phase l/ll clinical trial of NV1205 for the treatment of patients with childhood cerebral adrenoleukodystrophy (CCALD).